Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:10
Regulatory News Service
Załącznik 2_Strategia ESG Mabion S.A.
Polish 11.7 MB
2025-11-17 14:10
Regulatory News Service
Załącznik 1_Strategia Mabion S.A.
Polish 1.4 MB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
English 8.3 KB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
Polish 8.8 KB
2025-10-24 20:35
Related Party Transaction
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (EN)
English 2.5 KB
2025-10-24 20:35
Capital/Financing Update
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (PL)
Polish 2.4 KB
2025-10-08 15:16
Audit Report / Information
Informacja dotycząca stanowiska Zarządu i opinii Rady Nadzorczej Mabion S.A. od…
Polish 264.8 KB
2025-10-08 15:16
Interim Report
Raport Biegłego Rewidenta
Polish 497.9 KB
2025-10-08 15:16
Interim Report
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Polish 228.5 KB
2025-10-08 15:16
Management Discussion and Analysis
Mabion_Sprawozdanie Zarządu_1H2025
Polish 3.2 MB
2025-10-08 15:16
Interim Report
Mabion MSSF_1H2025
Polish 3.4 MB
2025-10-08 15:16
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (EN)
English 1.0 KB
2025-10-08 14:27
Report Publication Announcement
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (PL)
Polish 784 bytes

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mabion S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan
4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden
KLAR
Klotho Neurosciences, Inc. Logo
Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.
United States of America
KLTO
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan
9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan
4967
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America
KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan
177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea
102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America
950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea
041960

Talk to a Data Expert

Have a question? We'll get back to you promptly.